UFF
NBIX icon

USA Financial Formulas’s Neurocrine Biosciences NBIX Stock Holding History

USA Financial Formulas’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-174
Closed -$24.7K – 501
2025
Q4 		$24.7K Buy
+174
New +$25.2K ﹤0.01% 253
2024
Q3 		– Sell
-243
Closed -$33.5K – 340
2024
Q2 		$33.5K Sell
243
-87
-26% -$11.9K 0.01% 243
2024
Q1 		$45.5K Buy
+330
New +$45.1K 0.01% 243
2023
Q2 		– Sell
-5
Closed -$506 – 500
2023
Q1 		$506 Buy
+5
New +$520 ﹤0.01% 363
2018
Q1 		– Sell
-6,511
Closed -$505K – 375
2017
Q4 		$505K Buy
+6,511
New +$444K 0.12% 142

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

USA Financial Formulas's NBIX Position: Q1 2026 in Review

USA Financial Formulas sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 174 shares — an estimated $24.7K sold.

USA Financial Formulas first reported a position in NBIX in Q4 2017 and held it in 5 quarters. The position peaked at $505K in Q4 2017. 697 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • USA Financial Formulas reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • USA Financial Formulas sold 174 Neurocrine Biosciences shares in Q1 2026, an estimated $24.7K.
  • USA Financial Formulas first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 5 quarters.
  • USA Financial Formulas's Neurocrine Biosciences position peaked at $505K in Q4 2017.
  • 697 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on USA Financial Formulas's 13F filing for Q1 2026, filed 14 Apr 2026.